Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Houlihan Lokey enters its October 28 earnings date with an unusually clear-cut insider signal cutting against a stock that has lost nearly 7% over the past month.
The standout from this week's data is the August 3 open-market purchase by CFO Lindsey Alley. She paid $124.52 per share for 4,020 shares, committing $500,570 of her own capital. That trade was not made under a 10b5-1 plan, making it a discretionary call at a level well below where the stock changed hands before July's results. The stock has since recovered to $127.94, up about 2.7% on her entry price, but still sits roughly 15% below the $150-plus levels the stock traded at before the July 29 earnings miss. Separately, a director received a routine grant of 925 shares on October 1, and the General Counsel exercised and sold 1,000 shares in September, a mechanics transaction rather than a conviction signal. Net across the past 90 days, insiders are modestly net long by about 3,020 shares and $360,000 in value, with the CFO purchase doing the heavy lifting.
Short positioning is modest and trending lower, leaving the lending market as little more than background noise ahead of the print. Short interest is running at 4.7% of the free float, down 2.1% over the past week and only fractionally above where it sat a month ago. Borrow costs are minimal at 0.38%, barely changed over 30 days. Availability is exceptionally loose: nearly 48 million shares remain available to borrow against roughly 2.5 million already short, giving an availability ratio above 3,200%. There is no squeeze dynamic here, no elevated borrow demand, and no sign the lending market is pricing in an event. The ORTEX short score has drifted down from 38.2 to 37.7 over the past two weeks, confirming bears are not adding pressure into the print. Options lean the same way: the put/call ratio at 0.31 is below its 20-day average of 0.35 and sits about one standard deviation to the bullish side, meaning options traders are, if anything, skewed toward calls rather than hedging.
The Street's read is more mixed than the positioning implies. The analyst consensus sits at a mean target of $154.50, about 21% above the current price, and most firms are still constructive. UBS raised its target this week from $147 to $154, maintaining a Neutral rating, a positive incremental signal from a firm that is not a bull. Goldman Sachs carries a Buy with a $148 target, and Morgan Stanley remains Overweight at $177. The caveat is that the whole cluster of targets was reset lower in the wake of the July earnings miss: Goldman cut from $171 to $148, Morgan Stanley from $187 to $177, and KBW from $160 to $153, all on July 30. The mean target has recovered slightly since then but still reflects a Street that sees value while acknowledging the near-term earnings risk. The PE ratio has contracted about 1.4 turns over the past 30 days to roughly 15.4x, while the price-to-book has eased by about 0.24x to 3.26x. Factor scores are divided: forward EPS growth scores in the 100th percentile, and the dividend factor ranks 97th, but 90-day EPS momentum is in the 14th percentile, a reminder that estimate revisions have been moving the wrong way on the longer trend.
On ownership, the activist register carries two Schedule 13D filers worth flagging. HL Voting Trust and A&R Voting Trust hold 22.9% and 22.5% of the class respectively as last disclosed, a combined stake of roughly 45% that reflects the firm's employee-controlled structure rather than external activist pressure. These are insider voting blocks, not agitators. BlackRock remains the largest third-party institutional holder at roughly 7.5% as of September 30, having added 75,000 shares in the most recent period. Capital Research and Management made a notable move, adding nearly 795,000 shares to reach 1.33% of outstanding shares. As always with 13D/G filings, stakes are as last disclosed and holders dropping below 5% may exit without a further filing.
The July 29 results remain the sharpest reference point for October 28. The stock fell 11.8% on the day of that print and gave back nearly the same amount over the following five trading sessions, a rare case where the initial drop held rather than partially reversed. The question heading into the next quarter is whether the advisory pipeline has stabilised since then, and whether Alley's August purchase at $124.52 reflects inside confidence in an inflection or simply a value call on a structurally profitable franchise. Wikipedia page views are running at a z-score of 3.2 versus their own 90-day history, a notable spike in retail attention that may reflect the earnings approach rather than anything fundamental.
Watch whether the earnings date on October 28 produces another negative day-one move or breaks the pattern established over the past two quarters, particularly given that the CFO's discretionary purchase sits inside the current price band.
See the live data behind this article on ORTEX.
Open HLI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
